Barbara Tilley to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Barbara Tilley has written about Randomized Controlled Trials as Topic.
Connection Strength
0.778
-
Quasi-likelihood estimation for relative risk regression models. Biostatistics. 2005 Jan; 6(1):39-44.
Score: 0.180
-
Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions. Clin Trials. 2020 12; 17(6):627-636.
Score: 0.133
-
Continuous time Markov chain approaches for analyzing transtheoretical models of health behavioral change: A case study and comparison of model estimations. Stat Methods Med Res. 2018 02; 27(2):593-607.
Score: 0.098
-
Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion. 2015 Jun; 55(6):1331-9.
Score: 0.092
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
Score: 0.039
-
Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: data from the NINDS t-PA stroke trial. Stat Med. 2001 Jul 15; 20(13):1891-901.
Score: 0.035
-
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996 Nov; 27(11):2136-42.
Score: 0.026
-
Communicating with participants during the conduct of multi-center clinical trials. Clin Trials. 2016 12; 13(6):592-596.
Score: 0.025
-
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29; 384(9958):1929-35.
Score: 0.022
-
Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010 Jun 15; 25(8):1082-6.
Score: 0.016
-
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010 May 15; 375(9727):1695-703.
Score: 0.016
-
Caffeine and progression of Parkinson disease. Clin Neuropharmacol. 2008 Jul-Aug; 31(4):189-96.
Score: 0.014
-
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006 Oct; 37(10):2508-13.
Score: 0.013
-
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006 Jul; 37(7):1798-804.
Score: 0.012
-
Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. Biometrics. 2005 Jun; 61(2):532-9.
Score: 0.012
-
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 06; 363(9411):768-74.
Score: 0.011
-
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004 Feb 04; 291(5):576-84.
Score: 0.011
-
Self-administered joint counts and standard joint counts in the assessment of rheumatoid arthritis. MIRA Trial Group. Minocycline in RA. J Rheumatol. 1999 May; 26(5):1065-7.
Score: 0.008
-
Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999 Apr; 30(4):905-15.
Score: 0.008
-
Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. Am J Cardiol. 1990 Jul 15; 66(2):129-33.
Score: 0.004
-
Effects of cigarette smoking and propranolol in survivors of acute myocardial infarction. Am J Cardiol. 1990 Feb 01; 65(5):271-6.
Score: 0.004